FMS-like tyrosine kinase-3 (FLT3), a receptor tyrosine kinase, is important for the development of the hematopoietic and immune systems. Activating mutations of FLT3 are now recognized as the most common molecular abnormality in acute myeloid leukemia, and FLT3 mutations may play a role in other hematologic malignancies as well. The poor prognosis of patients harboring these mutations renders FLT3 an obvious target of therapy. This review summarizes the data on the molecular biology and clinical impact of FLT3 mutations, as well as the therapeutic potential of several small-molecule FLT3 inhibitors currently in development.
Introduction
Acute myeloid leukemia (AML) is an aggressive malignancy that generally leads to a poor outcome. 1 Deregulated tyrosine kinase activity has long been implicated in the molecular pathogenesis of cancer, including leukemia, and mutant forms of KIT, ABL, and platelet-derived growth factor receptor (PDGF-R) number among the constitutively activated tyrosine kinases that have been identified as causative factors in specific hematologic malignancies. [2] [3] [4] FMS-like tyrosine kinase-3 (FLT3), a member of the PDGF-R subfamily of receptor tyrosine kinases, is the most recent major addition to this list. [5] [6] [7] Acute leukemia is thought to arise from leukemic stem cells, the properties of which have only recently begun to be characterized. 8, 9 FLT3 was originally identified by its expression in hematopoietic stem/progenitor cells, and its importance in normal lymphohematopoietic stem cell function is now well established. [10] [11] [12] Not surprisingly, this receptor appears to play an important role in the pathogenesis of acute leukemia, particularly AML. In the past 7 years, beginning with the identification of internal tandem duplication mutations of FLT3 (FLT3/ITD mutations), 13 a wealth of literature has emerged detailing the frequency and prognostic impact of FLT3 activating mutations in AML. New insights into the pathogenesis of the disease have also emerged from this work.
The purpose of this review is to summarize this recent body of literature pertaining to the role of FLT3 in AML, with particular emphasis on FLT3 activating mutations, and including the results of recent efforts to develop small-molecule FLT3 inhibitors for therapeutic use. A detailed review of the function of FLT3 in normal hematopoietic stem cells and in the immune system, as well as outside the lymphohematopoietic system, is beyond the scope of this report. For these subjects, the reader is referred to previous excellent reviews. 10, 14 
FLT3 receptor and ligand
The gene for human FLT3, cloned independently by two groups, was at one point designated STK-1 (stem cell tyrosine kinase-1) by virtue of its having been cloned from a cDNA library derived from CD34-positive cells. 7, 15 It was recognized as having 92% amino-acid homology with the murine gene, which had been cloned earlier, again from a stem cell-enriched cDNA library. 5, 6 The mouse gene was alternately named FLK-2 (fetal liver kinase-2) or FLT3, and this latter designation has emerged as the term most commonly used to describe both murine and human versions. Human FLT3 maps to chromosome 13 (13q12) and is comprised of 24 exons extending over more than 100 kilobases (kb). [16] [17] [18] FLT3 is a member of the PDGF-R subfamily (the socalled class III) of receptor tyrosine kinases, characterized by an interrupted kinase domain. 19 It has closest homology to FMS, KIT, and the two PDGF receptors, and lesser homology to the vascular endothelial growth factor and nerve growth factor receptor subfamilies. These relationships have potential importance with regard to the selectivity of small-molecule FLT3 inhibitors discussed below.
FLT3 ligand (FL) has also been cloned in both mouse and human, and this protein likewise appears to be structurally similar to CSF-1, the ligand for FMS, and to KIT ligand (KL). [20] [21] [22] FL is expressed in virtually every tissue thus far examined, so the function of this cytokine is more likely determined by the very narrow range of tissues expressing the FLT3 receptor, namely, hematopoietic and neural tissue. In human hematopoietic cells, FLT3 expression is restricted to the CD34-positive fraction of bone marrow and a smaller fraction of CD34-negative cells destined to become dendritic cells. 7, 23 Targeted disruption of either FLT3 or FL in mice, while not lethal in embryogenesis, leads to reduced numbers of bone marrow hematopoietic precursors in general and a reduction of lymphoid precursors in particular. 24, 25 A number of studies have shown that FL acts in synergy with other cytokines to promote expansion of hematopoietic precursors. [26] [27] [28] [29] [30] Work in both murine and human systems suggest that FLT3 expression and function are mainly associated with the so-called 'short-term' reconstituting hematopoietic stem cells, that is, those capable of multilineage myeloid reconstitution, but lacking unlimited self-renewal capacity. 11, 12 However, a recent study showed that in human CD34-positive cells, the FLT3-positive fraction has the active long-term reconstituting activity. 31 The accumulated data clearly point to FLT3 as an important receptor in early hematopoiesis.
FLT3 shares the structural features of the other members of its subfamily, namely five immunoglobulin-like domains in the extracellular region, a single transmembrane sequence, and, intracellularly, a short juxtamembrane portion followed by the interrupted kinase domain (Figure 1 ). 7, 19 Its activation signals are transduced through phosphorylation of cytoplasmic proteins in biochemical pathways that promote cell growth and inhibit apoptosis. Upon binding FL, the receptor dimerizes, activating its tyrosine kinase domain with resultant autophosphorylation.
Ras-GAP, PLC-b, PI3-kinase, STAT5, and MAP kinase are all important signaling proteins linked to activation of FLT3. [32] [33] [34] [35] [36] [37] 
FLT3 in leukemia
Given its apparent pivotal role in normal hematopoiesis, it is perhaps not surprising to find that FLT3 appears to play an important role in leukemia. FL expression has been demonstrated in the vast majority of human leukemia and lymphoma cell lines, while the FLT3 receptor is expressed in most pre-Bcell, myeloid, and monocytic leukemia cell lines. 38, 39 Recently, we have also found FL to be universally expressed by primary AML blasts. 40 In primary human leukemia cells, FLT3 is expressed in larger amounts (compared with normal bone marrow), and aberrantly expressed in that it is no longer tightly associated with CD34 expression. [41] [42] [43] In these studies, virtually all samples of B-lineage acute lymphocytic leukemia (ALL) examined and over 90% of AML cases demonstrated FLT3 expression, both as RNA and as functional protein. Likewise, a lesser portion of chronic myelogenous leukemia (CML) blast crisis, as well as chronic lymphocytic leukemia (CLL) and even T-cell ALL cells have been shown to express FLT3. [41] [42] [43] The SEMK2-M1 leukemia cell line has been found to contain an amplification of the wild-type FLT3 gene. 44 It is not known if this mechanism might explain the overexpression of FLT3 seen in many primary samples of leukemia. Primary leukemic blasts and leukemia cell lines frequently respond to the addition of the ligand in vitro, or coexpress FL themselves, all leading to the stimulation of proliferation and inhibition of apoptosis. 39, [45] [46] [47] [48] [49] Since FL is widely expressed in normal tissues and often coexpressed within leukemia cells, aberrantly expressed or overexpressed FLT3 might lead to constitutive dimerization and activation of the receptor. 38, 50, 51 Finally, mice transplanted with bone marrow transduced with a vector that constitutively expressed human FL have a predisposition to develop leukemia. 52 Thus, several lines of evidence now implicate the FLT3 receptor-ligand combination in leukemogenesis.
FLT3 activating mutations
A number of FLT3 activating mutations have been found in leukemia patients and human leukemia-derived cell lines. The first of these to be identified was the FLT3/ITD mutation. 13 Subsequent to this, two independent groups identified activating point mutations at aspartate 835 (or isoleucine 836) in the activation loop of the FLT3 kinase domain. 53, 54 Both types of mutations are primarily found in AML, and a considerable body of data has now accumulated regarding their incidence and clinical impact.
FLT3/ITD mutations
The FLT3/ITD mutations were discovered through the use of a reverse transcriptase-polymerase chain reaction (RT-PCR) assay to screen a series of primary leukemia specimens for FLT3 expression. A recurring abnormality was noted in the FLT3 transcripts from AML patients. 13 When primers flanking the juxtamembrane portion of the FLT3 coding sequence were used to amplify cDNA, an unexpectedly longer amplification product was observed in five out of 22 AML samples. DNA sequencing revealed these samples to harbor in-frame, internal tandem duplication mutations of nucleotide sequence within exon 14.
(This was originally reported as exon 11, but once the human genome sequence became available, examination of the entire gene established that FLT3 was encoded over 24, rather than 21, exons. 18 ) A schematic of the FLT3 receptor and sample of the assay is shown in Figure 1 . Patients with this abnormality were found to have an increased incidence of leukocytosis and a decreased overall survival (OS) when compared with patients without FLT3/ITD mutations. These seminal findings shifted a considerable amount of attention to the role of FLT3 in AML. Numerous groups around the world have now confirmed and extended these findings in both adult and pediatric AML. Leukemia-derived cell lines have also been examined for the presence of FLT3 mutations, and four have been identified (MV4-11, MUTZ-11, MOLM-13, and PL-21) that harbor FLT3/ ITD mutations. [78] [79] [80] Of these, only the MV4-11 cell line actually expressed easily detectable FLT3 receptor protein, which was, in fact, constitutively autophosphorylated.
FLT3/ITD mutations are reported to range in size from 3 to more than 400 bp, 70 and always occur in multiples of three so that the reading frame is maintained. They are usually contained within exon 14, typically, but not always, near residues 590-600 of the FLT3 amino-acid sequence. Occasionally, the duplicated region extends through the 90 bp intron between exons 14 and 15 and includes a portion of exon 15. The duplicated sequences are often preceded by inserted (nonduplicated) nucleotides, but the resultant transcript is always inframe. One group has reported a triplication of sequence. 61 Internal tandem duplications are not unique to FLT3, as similar mutations have been reported to occur in the related receptor KIT (in canine mastocytomas) and in other (nonhuman) genes. 81, 82 Partial tandem duplications of the mixed lineage leukemia (MLL) gene have been found in both AML and ALL, sometimes in conjunction with an FLT3/ITD mutation. [83] [84] [85] [86] The cause of these duplication events has been speculated upon, but remains unknown. One proposed mechanism was that, during DNA replication, a palindromic sequence in the lagging strand forms a hairpin structure, which then leads to a duplicated sequence if mismatch repair is impaired in any way. 87 Others have proposed a slippage-repair mechanism following simulta- Figure 1 A diagram of the FLT3 receptor (top), with a schematic of the FLT3 cDNA and primers (middle) for the RT-PCR reaction (bottom) used to detect the presence of the internal tandem duplication mutation.
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FLT3 receptors containing ITD mutations are constitutively autophosphorylated, at least when these receptors are expressed in COS-7, Ba/F3, or 32D cells. 79, [87] [88] [89] Thus far, there has been no published data indicating that the exact length or location of the duplicated sequence influences the degree of autophosphorylation. In the FLT3/ITD-transfected cell lines, phosphorylation of the mutant receptors appears to be maximal, in that it is not augmented by the addition of exogenous FL. 90 However, the mutant receptors generally are expressed at high levels, which may in itself influence autophoshorylation. The FLT3/ITD receptors not only homodimerize, but they also heterodimerize with the wild-type receptor, again, independent of ligand. 91 It is generally assumed that ITD-containing FLT3 receptors are constitutively activated in primary leukemia cells, but the data supporting this is actually somewhat limited. In three separate reports in which the phosphorylation of FLT3 within AML blasts harboring FLT3/ITD mutations was analyzed, only 12 of 18 cases demonstrated FLT3 autophosphorylation, with one of the reports suggesting no correlation between mutation status and phosphorylation. 79, 92, 93 In most cases, the addition of exogenous FL enhanced FLT3 phosphorylation, although this may be the result of activation of wild-type FLT3 receptors expressed by the cells. To more thoroughly address the issues of constitutive activity and ligand responsiveness of ITD-mutated FLT3 in primary leukemia blasts, a number of variables will have to be accounted for, including cell culture conditions, the amount of receptor expressed, the ratio of mutant-to-wild-type receptor, and coexpression of FL. It may be that the ITD-mutated receptor is still ultimately ligand dependent, but the ubiquitous nature of FL expression renders the issue moot. Regardless, the available evidence to date strongly supports the notion that the FLT3/ITD mutation is associated with constitutive FLT3 autophosphorylation.
The mechanism whereby ITD mutations cause constitutive kinase activity in FLT3 has not been fully elucidated, as there is currently no crystal structure data available for the FLT3 receptor. Recently, structural and mutational analysis of EphB2, a member of the Eph receptor tyrosine kinase subfamily, has provided some insight into this issue. 94 In the inactive EphB2 receptor, components of the juxtamembrane domain, including two tyrosine residues (Y604 and Y610), are closely associated with an alpha helix of the N-terminal lobe of the kinase domain. This association prevents the activation loop within the kinase domain from assuming an active conformation. The EphB2 model predicts that phosphorylation of tyrosine 610 (corresponding to tyrosine 591 of FLT3) would destabilize this association, relieving the steric constraints to the activation loop. If a similar mechanism holds true for FLT3, then the ITD mutations might be predicted to act in cis to disrupt the juxtamembrane domain's steric hindrance of the kinase domain, leading to constitutive autophosphorylation. However, when an ITD-containing version of FLT3 in which the kinase domain is inactivated through truncation is coexpressed with wild-type FLT3, the mutation seems to operate in trans. 91 Interestingly, the juxtamembrane domain of the TGFb receptor seems to exert its regulatory effect through the binding of an inhibitory protein. 95 Therefore, while it seems clear that the juxtamembrane region of many receptors, including FLT3, exerts a negative regulatory effect on kinase activity, more than one mechanism may be employed to accomplish this effect. 96 Activating mutations localized to the juxtamembrane region are also found in other members of the PDGF receptor subfamily, further supporting an autoinhibitory role for this domain. [97] [98] [99] An activating tandem duplication within the juxtamembrane region of KIT was identified in a canine mastocytoma, and a variety of activating point mutations within this region of the receptor have been found in human gastrointestinal stromal tumors. 81, 100 An activating juxtamembrane point mutation was also identified in the PDGF receptor. 97 
Signaling through constitutively activated FLT3
A variety of data suggests that mutation-activated FLT3 may have different signaling properties compared with the wild-type receptor. Most notably, constitutively activated STAT5 appears to be associated with constitutively activated FLT3. STAT5 is constitutively phosphorylated in Ba/F3 and 32D cells transfected with constitutively activated FLT3 constructs, but not when the same cells are transfected with wild-type FLT3. 88, 101 Constitutively phosphorylated STAT5 has also observed in primary AML blasts harboring FLT3/ITD mutations. 79, 88, 93 Finally, the cytotoxic effects of an FLT3 inhibitor (see below) on AML blasts appeared to correlate best with inhibition of STAT5. 79 It is possible that the differences between the targets activated by the wild-type and constitutively activated FLT3 receptors are brought about by quantitative or even qualitative differences in the tyrosine kinase activity of the receptor. That is, FLT3 activating mutations may result in continuous phosphorylation of target proteins, without a compensatory receptor downregulation, or they may lead to the phosphorylation of targets not normally present within the FLT3 signaling pathway. For example, wild-type FLT3 has been shown to signal through Ras-GAP, PI3-kinase, Grb2, SHP-2, Shc, and Vav. [32] [33] [34] [35] [36] [37] Constitutively activated FLT3, expressed in murine cell lines, has likewise been demonstrated to activate MAP kinase (presumably via Ras activation) and AKT (downstream of PI3-kinase). 88, 89 However, in these experimental systems, Jak2, STAT3, and CBL were also identified as activated by constitutively activated FLT3, but not by wild-type FLT3. 101 In primary blasts, MAP kinase phosphorylation was observed in samples harboring FLT3/ITD mutations, but the cytotoxic effects of FLT3 inhibition did not appear to correlate as well with inhibition of MAP kinase. 79 
Biological consequences of abnormal FLT3 activation
On a cellular level, mutation-activated FLT3 confers factor independence and induces transformation in Ba/F3 and 32D cells. In 32D cells, it completely blocks G-CSF-induced differentiation of 32D cells and suppresses the expression of myeloid transcription factors. 102, 103 Furthermore, recent microarray data have demonstrated the upregulation of the PIM-1 and/ or PIM-2 genes in association with constitutively activated FLT3. 103, 104 A number of mouse model systems have provided important insight into the biological impact of FLT3 activating mutations. Primary AML blasts harboring FLT3/ITD mutations have been noted to engraft NOD/SCID mice much more efficiently than samples lacking the mutation. 59, 105 Curiously, however, primary samples harboring mutations show a reduced proliferative capacity in vitro. 59, 106, 107 Balb/c or C3H mice injected with syngeneic cells transformed with activated FLT3 constructs die of a leukemia-like disease. 79, 89, 101 Similarly, NOD/SCID mice injected with MV4-11 cells (which harbor an FLT3/ITD) or NOD/beige mice injected with SEMK2-M1 cells (which over- express FLT3 through a naturally occurring gene amplification) develop leukemic infiltrates and die within weeks of injection. 44, 108 Transgenic mice expressing the constitutively activated TEL-FLT3 construct develop a myeloproliferative syndrome, as do Balb/c mice transplanted with bone marrow cells transduced with a retroviral FLT3/ITD construct. 109, 110 When PML/RARa bone marrow cells are transduced with a retrovirus expressing the FLT3/ITD gene and then transplanted back into mice, the mice develop an acute promyelocytic leukemia (APL)-like illness with complete penetrance and decreased lag time. [111] [112] [113] In summary, because of the profound biochemical consequences of its constitutive activation, FLT3 mutations probably play a fundamentally important role in human leukemogenesis.
Clinical implications of FLT3 mutations

Incidence of FLT3/ITD mutations in AML
At the time of this writing, there are more than 20 published series reporting incidences of FLT3/ITD mutations in adult and pediatric AML populations, comprising over 5000 patient samples. Several additional studies have been reported in abstract form. Not included in these totals are studies of infant AML (in which no FLT3/ITD mutations were found) and treatment-related AML (in which the incidence was found to be 3.7%). 114, 115 Of these studies, 21 are summarized in Table 1 , grouped according to AML category.
Examination of Table 1 reveals an important aspect of the individual FLT3/ITD studies, namely that many involve only a subset of AML patients. This explains the relatively wide variation in incidence rates and also renders the larger studies particularly important. Much of the data from these later studies are reported both as a whole and broken down by prognostic category, allowing a crosscomparison with the several smaller studies. The results are, in general, consistent across all categories, and several important features are evident. First, two large categories of AML patients with FLT3/ITD mutations stand out, namely those comprised of adults with normal or intermediate-risk cytogenetics, and those with APL. Second, the incidence in pediatric AML is lower than that of the incidence in the adult population (see below). Third, the incidence is consistently lower in patients with core-binding factor translocations (8;21 and INV16) and poor-risk cytogenetics. The increased and decreased incidences of mutations, depending on the prognostic subgroups studied, provide the explanation for the variation in reported incidence. For example, in one study (Table 1 , study 5), only patients with normal or good-prognosis cytogenetics were screened for FLT3/ITD mutations. Nearly half (52 out of 106) of the cases harbored core-binding factor translocations, which other studies have shown correlates with a decreased frequency of FLT3/ITD mutations. Not surprisingly, this study reported an overall FLT3/ITD incidence of 13.2% in their series. In contrast, another study (Table 1 , study 8) examined only AML cases with normal cytogenetics, and found 28% positive for FLT3/ITD mutations.
Overall, in analyzing the composite frequencies in Table 1 , FLT3/ITD mutations can be estimated to occur in 22.9% of adult de novo AML cases, and in 12.6% of childhood AML. In AML derived from myelodysplastic syndromes (MDS-AML), the incidence of the mutations appears to be somewhat lower than in de novo AML (15.6%), but in cases of myelodysplasia alone (ie, before the development of AML), the frequency as reported by one group is low (3%; Table 1 , study 1). This would imply 22.2% (10/45) that, at least in MDS-AML, the FLT3/ITD mutation is more often a late event, perhaps triggering the development of a condition analogous to the blast crisis phase of CML. Among all human hematologic malignancies thus far examined, AML was originally thought to be the only disease associated with a significant frequency of FLT3/ITD mutations. The so-called MLLs however, which harbor MLL gene rearrangements and which are now recognized as a disease entity distinct from ALL, have recently been found to also harbor a high rate of FLT3 mutations. 44 The mutation rate is low in MDS and ALL, and the mutation has not been found in myeloma, lymphoma, CLL, or the myeloproliferative disorders. 78, 116, 117 Any attempt to estimate the incidence of FLT3/ITD mutations in AML patients will be influenced by a number of factors. The population being studied is clearly important, as the mutation incidence varies significantly between AML subtypes, particularly those subgroups defined by cytogenetic abnormalities. Also, many of the results summarized in Table 1 were derived from studies using banked leukemia specimens, which typically represented only a fraction of the AML patients treated at the institution or in the cooperative group. This use of banked samples would be expected to select for patients with higher peripheral white blood cell (WBC) counts and packed bone marrows. This bias was confirmed in the two studies that examined this issue (Table 1 , studies 6 and 12). Using samples derived from cooperative group studies, it was determined that specimens screened for FLT3/ITD mutations were obtained from patients with significantly higher WBC counts than patients for which no material was available. Since leukocytosis is one of the most consistent clinical features of FLT3/ITD AML, the incidences in Table 1 may overestimate, to some degree, the true incidence of the FLT3/ITD mutation. A large, prospective study will probably be necessary to estimate the incidence of this mutation in AML accurately.
Other factors that may impact estimates of the incidence of FLT3/ITD mutations are the use of peripheral blood instead of bone marrow as the source of DNA or RNA, and the amplification techniques used. One group used a single-strand conformation polymorphism analysis to detect additional FLT3/ ITD mutations not identified in the standard gel mobility assay depicted in Figure 1 . The great majority of the results summarized in Table 1 , however, were derived using genomic DNA isolated from diagnostic bone marrow samples.
Clinical features of AML associated with FLT3/ITD mutations
Leukocytosis: FLT3/ITD mutations are uniformly associated with an elevated mean WBC count at diagnosis. In the studies listed in Table 1 , all but three of the adult series analyzed this clinical variable at diagnosis, and all reported a significantly higher (typically greater than two-fold) mean WBC in the cases harboring FLT3/ITD mutations as compared with those expressing wild-type FLT3. A similar degree of leukocytosis is also consistently associated with mutations in the pediatric studies. Several of the adult studies also examined the percentage of blasts in the diagnostic bone marrow samples and reported a significant increase in this percentage.
Age: Within the adult AML population, only one study (Table 1 , study15) has reported an association between the incidence of the mutations and patient age (and this was a minor difference). Among adults, then, there appears to be no correlation between patient age and FLT3 mutation status. In the pediatric population, three of the five studies listed in Table 1 reported FLT3/ITD mutations to be more frequent in patients aged 10 years and older. One study even noted that the frequency of the mutation in children over 10 years was 24%, similar to the adult frequency. Of the 58 pediatric AML cases with FLT3/ITD mutations published in these studies, 39 were aged 10 years and older. It is tempting to conclude, therefore, that the incidence of FLT3/ITD mutations is approximately 23% in any AML patient (adult or child) over the age of 10 years, while they are much less frequent in younger children.
FAB status: FLT3 mutations are clearly more common within the M3 subtype. In general, however, the studies listed in Table 1 report a fairly even distribution of FLT3/ITD mutations across all the other FAB subtypes, with one intriguing exception. Two groups have noted an increased incidence of FLT3 mutations within the M5 subtype and one found a significantly higher incidence (28.8%) within the M5b subgroup in particular. 69, 70, 118 Complete remission: The majority of the adult AML studies listed in Table 1 found no difference in the complete remission (CR) rates between wild-type and mutant FLT3 cases. One large study (Table 1 , study 7) did report a significantly lower CR rate in the cases with a mutation, but the difference was relatively small (78% CR rate in FLT3/ITD patients vs 84% in wild-type FLT3 patients).
In contrast, two pediatric studies (Table 1 , studies 11 and 12) analyzed this clinical variable in FLT3/ITD vs wild-type FLT3 cases and both studies found a significant decrease in CR rate associated with the mutation.
Prognosis: Of the 16 adult AML studies listed in Table 1, 15 provided statistical analyses of survival data, and of these 15 studies, all but one found significant decreases in OS, diseasefree survival (DFS) or event-free survival (EFS) in some way associated with FLT3/ITD mutations. However, interpretation of any data about the prognostic impact of these mutations should take into consideration the AML subgroups being studied, the type of mutation, the number of patient samples used, the duration of follow-up, FLT3 mutant-to-wild-type ratios, and the treatment regimen(s) that the patients received. Table 2 summarizes studies that provided an estimate of OS in adult patients harboring FLT/ITD mutations.
Adult AML: Two relatively large early studies of FLT3/ITD mutations in adult AML ( Table 2 , studies 1 and 6) included most subtypes of AML in their analyses and estimated 5 years OS rates for patients with and without FLT3/ITD mutations. These studies provided long-term follow-up (50 þ months) for over 1000 patients, and utilized comparable, older treatment regimens employing standard doses of daily cytarabine (behenoyl cytarabine at 200 mg/m 2 /day for 10 days or cytarabine 100 mg/m 2 /day for 10 days), daunorubicin, and etoposide. Both studies found that the presence of these mutations was clearly associated with a worse clinical outcome. These results are graphically displayed in Figure 2 (left panel) . The difference in the magnitude of negative effect on survival between the two studies may be due, in part, to the exclusion of M3 AML cases by one of the studies. 57 Given that most groups have found that the prognosis of APL is less affected, or even unaffected, by the presence of FLT3/ITD mutations (see below), the exclusion of AML M3 from this study would tend to widen the observed Three more recent studies (Table 2 , studies 7, 8, and 10) provide somewhat more conflicting results. All three studies were derived from samples of patients in protocols utilizing relatively more intensive treatment regimens, particularly emphasizing early use of high-dose Ara C (2-3 g/m 2 every 12 h for 6 days). The study with the longest median follow-up (34 months) examined outcomes in patients with normal cytogenetics and found a significant decrease in survival associated with FLT3 mutations. 73 The other two studies had median follow-ups of only 11.1 and 12.2 months. Both groups found significant reductions in EFS or DFS, but no reduction in OS, in patients with FLT3/ITD mutations with this limited follow-up time. On the other hand, another study (Table 2, study 9) found no difference in outcomes associated with FLT3 mutations in patients receiving reinforced chemotherapy regimens (daunorubicin 80 mg/m 2 /day for 3 days7cytarabine 500 mg/m 2 every 12 h for six doses). 71 Longer follow-up data from all of these studies may clarify this issue. It is worth noting that one group 69 found a clear association between a high mutant-to-wild-type ratio and poor outcome, in agreement with an earlier finding. 63 The preponderance of published evidence indicates that the presence of an FLT3/ITD mutation is a significant, independent predictor of a poor clinical outcome in at least some subgroups of adult AML. As many of the studies listed in Table 1 are focused on different subgroups of AML patients, however, and because the duration of clinical follow-up reported is often considerably different, it is difficult to compare survival data directly from these studies to determine the overall prognostic impact of FLT3/ITD mutations. Moreover, the variable incidence of these mutations between different AML subgroups would be expected to influence the prognostic impact. For example, several studies have now confirmed a low incidence of FLT3/ ITD mutations in the subgroup of AML patients with a corebinding factor translocation (8;21 or INV16), a subgroup of AML that is generally regarded as having a better prognosis. 119 One study (Table 1 , study 5) examined the incidence and prognostic impact of FLT3/ITD mutations in AML patients with intermediate-and good-risk cytogenetics, and of the 106 patients in this series, 52 (49%) had 8;21 or INV16 translocations. They reported a mean survival of only 12.8 months for patients with an FLT3/ITD mutation, as compared with 29.1 months for those lacking a mutation (P ¼ 0.0002), which represented a significant negative prognostic impact. This observation can be interpreted in two ways. On the one hand, the poor outcome seen in association with FLT3/ITD mutations could be the result of a comparison with a favorable subgroup of patients. On the other hand, the possibility must at least be raised that the reason that core-binding factor AML has a good prognosis has less to do with the translocation and more to do with the absence of FLT3/ ITD mutations. In other words, perhaps it is the lack of an FLT3 activating mutation, rather than the presence of an 8;21 or INV16 abnormality, that improves outcomes in these patients.
As another example of how studying FLT3 mutations within AML subgroups might affect the interpretation of prognostic impact, in a study of elderly AML patients (Table 1 , study 6), FLT3/ITD mutations were not found to have any effect on clinical outcome. However, the median OS of all patients in this study was only 7 months. While this is not a surprising statistic for a study of AML in the elderly, the relatively short median survival of these patients may minimize the possible negative impact of FLT3/ITD mutations. Other factors potentially influencing prognosis are the type of mutation (ITD vs D835), 
Figure 2
Relative survival of AML patients harboring FLT3/ITD mutations (closed circles) compared with those patients with wild-type FLT3 (open circles) from four separate studies. The study numbers are the same as in Table 1. and the ratio of wild-type to mutant FLT3 (or loss of heterozygosity). Finally, earlier studies were derived from clinical trials that utilized older, less intensive chemotherapy regimens. Studies involving patients treated more intensively may yield different results regarding the prognosis of AML patients harboring FLT3 mutations.
Pediatric AML: In pediatric AML, the negative prognostic impact of FLT3/ITD mutations seems to be more dramatic ( Table 3 ). The results of EFS estimates at 5 or more years from two comparative studies are depicted in Figure 2 (right panel) . It should be noted that of the 461 total pediatric patients included in the six pediatric studies in 3 , 58 were found to have FLT3/ITD mutations, and, of these, only 11 patients were reported to have survived. This calculates to a 19% survival rate for FLT3/ITD patients compared with a 58% survival rate for patients with wild-type FLT3 in these pediatric studies. Thus, while the incidence of these mutations in pediatric AML is clearly lower than that in the adult patients, their presence appears to be even more ominous.
Acute promyelocytic leukemia: There have been three studies (Table 1 , studies 2, 17, and 19) that have reported survival data specifically for patients with APL harboring FLT3/ ITD mutations. Out of a total of 185 APL patients (30.3%), 56 harbored FLT3/ITD mutations. The majority of patients from whom these results were derived were treated with ATRA-based regimens. All three studies reported no significant difference in survival.
Mutant-to-wild-type ratio
A final important issue regarding FLT3/ITD mutations is the expression level of the mutant relative to the wild-type allele. One study identified eight out of 23 FLT3/ITD AML cases in which the presence of the wild-type allele was not detectable by PCR. 63 These patients were found to have a significantly higher peripheral WBC count compared to those cases in which the wild-type allele was detectable. The cases that lacked wild-type FLT3 altogether also had a distinctly worse clinical outcome (median survival of 7 vs 46 months). Semiquantitative PCR was used by another group to identify patients who expressed only mutant FLT3 and likewise found them to have a higher WBC count and the suggestion of a worse outcome. 62 Finally, in another study, patients with a mutant-to-wild-type ratio of 0.78 or greater were noted to have a significantly worse outcome than FLT3/ITD patients with a ratio less than 0.78, and worse than the FLT3/ITD group as a whole. 69 These findings represent compelling evidence that the FLT3/ITD mutation is not simply a manifestation of a global cellular phenomenon leading to genetic instability, but rather exerts a distinct biological effect in leukemia that may affect cell survival. The mechanism causing the altered ratio is attributed is some cases to loss of heterozygosity, 63 but this has not been a consistent finding. 69 It is clear, however, that even within a given patient, the mutant-to-wild-type ratio can fluctuate over time. Several different groups have examined the FLT3/ITD status in paired diagnostic and relapse AML samples. 58, 70, 120, 121 In general, the studies concluded that in some fraction of FLT3/ITD cases (probably 20% or less), the original mutation is not present at relapse. In addition, patients that were wild-type FLT3 at diagnosis appear to acquire de novo FLT3 mutations at relapse at a similar rate to that seen in newly diagnosed AML. Finally, in the cases that retained the mutation at relapse (which represented the majority of cases in all three studies), the mutant-to-wild-type ratio was often increased, as determined by semiquantitative methods.
Activation loop mutations
The aspartate residue at position 835 of FLT3, located within the activation loop of the kinase domain following the Asp-Phe-Gly motif, is conserved across several subfamilies of receptor tyrosine kinases. Activating point mutations of the corresponding residue in a number of different receptors have been identified, and, in the cases of KIT, MET, and RET, are associated with human malignancies. [122] [123] [124] [125] The D816 KIT mutations, in particular, have been found in human mast cell leukemias, and, although uncommon in AML, may be associated with corebinding factor leukemias. 126, 127 The mechanism whereby this type of mutation causes constitutive kinase activity is assumed to be the same as determined in other receptor tyrosine kinases, namely that the aspartate mutation stabilizes the activation loop in the 'open', ATP-binding conformation. 96, 122 Two independent groups of investigators reported finding FLT3 D835 (and, less often, I836) point mutations (most commonly aspartate to tyrosine) in AML patients. Both studies reported an approximately 7% incidence (seven out of 97 patients and 30 out of 429 patients) of the mutation. Neither study reported a significant effect of the presence of this mutation on OS, but the number of cases with available survival data was limited. Interestingly, these D835 mutations were not associated with leukocytosis. Three subsequent studies (Table 4) confirmed the approximately 7% incidence rate of these mutations in AML patients, and likewise did not find any dramatic effects on clinical outcome. 69, 73, 75 It may be that the signaling properties of the activation loop mutants differ from those of the ITD mutant receptors. It was also recently reported that five out of 30 MLLrearranged ALL specimens harbored FLT3 activation loop mutations.
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FLT3 D835 mutations are easily identified because they result in the loss of an EcoRV restriction enzyme site if either of the codons for D835 or I836 is mutated. A PCR product derived from the kinase domain that fails to digest with EcoRV signals the presence of this mutation. DNA sequencing is then used to confirm the result. COS-7 cells transfected with the D835 FLT3 cDNA display a constitutively activated receptor, as was seen with the FLT3/ITD mutations. A newer mutation, a 6 bp insertion within the activation loop of FLT3, has also been identified. 128 This mutation also causes constitutive phosphorylation of the receptor. 45 10 Decreased a All three patients with high mutant-to-wild-type ratios in this study died.
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Comparison with other mutations in AML
The 22.9% incidence of FLT3/ITD mutations combined with the 7.7% incidence of the D835 mutation gives an overall frequency of 30.6% for FLT3 mutations in adult AML. Constitutively activating mutations of FLT3 are therefore the most common genetic abnormality in this disease. Likewise, they are the most common molecular or cytogenetic abnormality affecting the clinical outcome in AML. The next most common mutation in AML with a clear negative prognostic impact is that of the MLL gene. Tandem duplications of the MLL gene have been discovered in 11% of AML patients with normal cytogenetics. When these cases are taken together with those cases having an 11q23 translocation, the MLL gene can be estimated to be altered in 6-8% of AML cases overall. 129 The cytogenetic abnormalities 5À, 5qÀ, 7À, and 7qÀ have all been associated with a poor prognosis, but together are present in only 8-10% of AML cases. 129 Oncogenic mutations of the RAS gene occur in 15-20% of AML, but appear to have little prognostic significance. 130, 131 Likewise, one study found six out of 15 cases (40%) of core-binding factor leukemias harboring D816 mutations of c-KIT, and mutations at codons 969 and 301 of the FMS gene have been reported to occur in up to 14-16% of AML cases. 132, 133 There is, however, no clear prognostic significance of these c-KIT and FMS mutations.
FLT3 inhibitors
The prognostic significance of FLT3 activating mutations in AML adds to the credentials of this receptor as a potential therapeutic target. While the recent preliminary clinical success of the ABL tyrosine kinase inhibitor imatinib mesylate in CML has provided an important precedent, the role of FLT3/ITD mutations in AML is perhaps more analogous to that of HER2 in breast cancer, or to that of the BCR-ABL mutation in Philadelphia chromosomepositive ALL. 134, 135 In each of these examples, like FLT3 in AML, the targeted gene product is but one of several alterations that causes the malignancy. HER2, a member of the ErbB receptor tyrosine kinase family, is amplified or overexpressed in 20-30% of patients with breast cancer. 136 These patients have been recognized as having a poor prognosis. 136 Treatment of this subset of breast cancer patients with trastuzimab (Herceptin, Genentech, South San Francisco, CA, USA), a monoclonal antibody directed against HER2, leads to improved survival, but not cures. 134 Likewise, the presence of BCR-ABL is an adverse prognostic factor in ALL, and the use of imatinib mesylate in the subset of ALL patients who harbor this mutation has resulted in favorable clinical responses (although again, without cures). 137 Translational research efforts have thus validated HER2 and the ABL kinase as therapeutic targets in these situations. However, inhibition of one 'hit' among the several that are likely responsible for these malignancies is insufficient to cure them.
The first FLT3 inhibitors to be identified were the tyrphostins AG1295 and AG1296. 90, 138, 139 These compounds, originally characterized as PDGF-R inhibitors, 140 inhibit FLT3 autophosphorylation in vitro (each with an IC 50 of 300 nM), and are cytotoxic to FLT3-dependent cell lines at doses that correspond to the inhibition of FLT3 autophosphorylation. Furthermore, AG1295 was selectively cytotoxic to primary AML blasts harboring FLT3/ITD mutations, a finding that further validates FLT3 as a therapeutic target. 139 Another compound, CEP-701, has been shown to inhibit very potently and more selectively FLT3 autophosphorylation in vitro and in vivo (IC 50 of 2-3 nM for FLT3 compared with an IC 50 of 4500 nM for KIT), and, like AG1295, is preferentially cytotoxic to leukemia cells harboring constitutively activated FLT3. 79 A number of additional small-molecule tyrosine kinase inhibitors with activity against FLT3 have now been identified (Table 5) . 79, 108, 112, 138, 139, [141] [142] [143] [144] [145] [146] These FLT3 inhibitors encompass a variety of chemical classes, but all are heterocyclic compounds containing a structural mimic of the purine component of ATP. While direct structural analysis of FLT3 is not yet available, analysis of the crystal structure data for a variety of other kinases bound to different small-molecule inhibitors allows some deductions to be made regarding the structure activity relationships of FLT3 inhibitors. Even though these compounds are all likely to fit into the ATP binding pocket of the receptor, some may do so via an induced fit mechanism (like the indolocarbazole staurosporine appears to do when binding to CSK), while others bind in a lock-and-key manner (such as imatinib binding to ABL). 147, 148 Inferring from the situation with other drugs, FLT3 inhibitors may bind to the active, inactive, or transitional state of FLT3. Selectivity for FLT3 may be greatly influenced by differences in single amino-acid residues between different receptors. For example, FLT3 is normally insensitive to inhibition by imatinib mesylate (IC 50 43 mM). However, substitution of Phe-691 with threonine renders the receptor susceptible to the drug (IC 50 0.1-0.3 mM).
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FLT3 inhibitors cause cell cycle arrest, inhibit proliferation, and induce apoptosis in a variety of FLT3-dependent cell lines. In a number of different studies, the FLT3 inhibitors displayed in Table 5 have been shown to be cytotoxic to the human leukemia-derived cell lines MV4-11, MOLM-13, MOLM-14, EOL-1, and SEMK2, all of which express constitutively activated FLT3. They likewise induce apoptosis in murine 32D and Ba/F3 cells transfected with FLT3/ITD constructs, and are selectively (Table 5) . 79, 90, 138, 139, [149] [150] [151] [152] Two of these, the indolocarbazole derivatives CEP-701 and PKC412, have been entered into phase II studies of relapsed and refractory AML patients with FLT3 activating mutations. The early results, presented in abstract form at the December 2002 American Society of Hematology meeting, were encouraging. 149, 153 Both were relatively small studies (each with less than 20 subjects), consisting of heavily pretreated, mostly elderly AML patients treated with oral CEP-701 or PKC412 as monotherapy. FLT3 inhibition in vivo was demonstrated in patients receiving the drugs, and neither compound appeared to cause significant toxicity. In these refractory, heavily pretreated AML patients, both drugs led to reductions in bone marrow blasts and peripheral blast counts, although the responses were often of short (1-3 months) duration. At least one patient treated with PKC412 achieved a complete response.
While there is certainly cause for optimism for this therapeutic approach in AML, a number of obstacles remain to be addressed. To begin with, potency will always be an issue in trying to introduce a new drug into human patients. In vitro potency may not necessarily translate into in vivo potency if the drug in question is highly protein bound. Since it is the free drug that exerts a biological effect, variability in plasma protein levels will lead to fluctuations in free drug levels, which in turn will influence clinical response. This already may be an issue with imatinib in CML. In addition, it is important to remember that none of these compounds are truly specific for FLT3. The preclinical data would suggests that in order to induce a cytotoxic effect in leukemia cells, FLT3 activity must be continuously inhibited to a level less than 10% of its baseline activity. Given the sequence similarities of the PDGF-R subfamily of receptor tyrosine kinases, it has not been surprising to find that many of the FLT3 inhibitors currently in development inhibit KIT and PDGF-R with nearly equal potency. One hypothetical concern with the clinical use of an FLT3 inhibitor in AML patients, therefore, is the possibility that such a compound might prevent or delay recovery from chemotherapyor leukemia-induced cytopenias, especially neutropenia. Simultaneous inhibition of FLT3 and KIT, in particular, might lead to prolonged marrow suppression, as suggested from experiments when FLT3-null mice were bred with mice expressing a partially inactivated allele of KIT. 24 This, of course, leads to a concern as to how FLT3 inhibitors will interact with chemotherapy. Given the number of mutations that probably contribute to leukemogenesis, as well as the development of drug resistance commonly seen in acute leukemia, 154 an FLT3 inhibitor as monotherapy in AML is unlikely to be effective for any significant duration of time. Designing an optimum combination regimen of inhibitor and chemotherapy will require effective integration of laboratory and clinical data. There is also the question of which patients will potentially benefit from FLT3 inhibitors. As most AML cells express FLT3, it is not surprising that some leukemia samples lacking activation mutations still respond in vitro to FLT3 inhibition. On the other hand, a minority of primary patient samples harboring FLT3/ITD mutations fail to respond to FLT3 inhibition (15-20%; see Levis et al 79 and unpublished data). In this regard, the development of laboratory methods for reliably predicting clinical response to FLT3 inhibition is important.
Do FLT3 mutations occur in leukemia stem cells?
A recently evolving paradigm in the field of cancer biology is that of cancer stem cells. 155 If a malignancy within a given patient arises from cancer stem cells that have the capacity for self-renewal, then targeted therapies should ideally be directed against these malignant stem cells. Most of the studies validating FLT3 as a therapeutic target in AML have been carried out using either tumor tissue (marrow samples), which contain only a small proportion of malignant stem cells, or using immortalized cell lines. The finding that AML samples harboring FLT3/ITD mutations have much greater engraftment potential in the NOD/ SCID mouse suggests that these mutations are usually intrinsic to the leukemia stem cell. 59, 105, 156 However, it remains to be seen if inhibiting FLT3 has the same effect on leukemia stem cells as it does on the progeny cells with limited self-renewal potential. Hypothetically, FLT3 activating mutations could simply be an epiphenomenon. In other words, the poor prognosis associated with these mutations may not be due to the mutations themselves, but rather to some feature of the leukemia stem cell, such as genetic instability, that both induces a tendency to develop FLT3/ITD mutations, and also, through mutations in other genes, results in resistance to conventional chemotherapy. These concepts then beg the question 'are FLT3 activating mutations present in leukemia stem cells?'
The data regarding mutant-to-wild-type ratios in diagnostic and relapse samples provide some tantalizing insights into this question. 63, 70, 120, 121 An observation that patients lacking a detectable wild-type FLT3 allele had worse clinical outcomes 63 was followed by larger studies that examined mutant-to-wildtype FLT3 ratios in paired diagnostic and relapse specimens. One group performed densitometric analysis of the ethidium bromide-stained PCR products and determined that, in 25 AML cases harboring FLT3/ITD mutations, all 25 samples retained the mutation at relapse, mostly at a higher mutant-to-wild-type ratio. 70 In contrast, another group, using 32 P-labelled primers and autoradiography for quantification, studied PCR results from 44 paired samples, 18 of which harbored FLT3/ITD mutations at the original diagnosis. 121 They found that six of the 18 mutant samples had completely lost the original mutation at relapse. One of these six was found to have a new FLT3/ITD mutation. The other 12 samples retained the original mutation, with six of these showing a higher mutant-to-wild-type ratio. They also observed that four patients who were originally wild type at presentation had acquired an FLT3/ITD mutation. Finally, a third group used a highly sensitive fluorometric method of quantitation to study 108 paired AML samples. 120 Of these patients, 16 had detectable FLT3/ITD mutations both at diagnosis and relapse. Eight patients originally wild-type acquired FLT3/ITD mutations at relapse. Interestingly, and perhaps owing to the greater sensitivity of their detection technique, this group identified eight patients with more than one FLT3/ITD mutation, but often at very low levels of mutant DNA (as low as 0.7% of the total). Among all the patients with FLT3/ITD mutations in this study, the mean level of mutant DNA increased from 17.9% at diagnosis to 40.5% at relapse.
To summarize these studies of paired diagnosis/relapse samples, the majority of AML cases harboring FLT3/ITD mutations relapse with an equal or higher level of the same mutation. A smaller, but not insignificant, number of patients relapse without the mutation, or with an entirely new one. For this small group of patients, it seems clear that the FLT3/ITD mutation is not present within the leukemia stem cell that ultimately leads to the patient's demise. However, interpretation of an FLT3 mutant-to-wild-type ratio is clearly complicated by FLT3 in leukemia M Levis and D Small the fact that the genomic DNA used for these assays is derived from a heterogeneous collection of cells, including some normal, nonmalignant cells. The characteristic double band (see Figure 1) on the agarose gel does not necessarily reflect the situation within a single leukemic blast. If the FLT3/ITD mutation is present within a leukemic stem cell and confers a growth advantage, then the clone containing the mutation would be expected to predominate as the disease progresses. If the mutation is originally present in heterozygous form, the mutant-to-wild-type ratio will approach 1.0 (ie, a mutant level of 50%). If loss of heterozygosity or gene conversion occurs, the mutant level will approach 100%. This would certainly explain the typically observed increase in the intensity of mutant signal in relapsed AML samples. On the other hand, the loss of the mutation at relapse (or a new mutation in a case that was wild type at diagnosis) suggests that they are truly 'late hits', occurring in a subclone of the original stem cell and resulting in a condition analogous to the blast crisis of CML. It is possible that both scenarios may occur. Consider a model in which the FLT3 activating mutation can occur at any of several different stages in the development of leukemia, and that such a mutation confers a growth advantage over leukemia cells lacking the mutation. In this model (Figure 3) , the mutant-to-wild-type FLT3 ratio depends on where, in the process of leukemogenesis, the FLT3 mutation occurs. If, for example, the mutation occurs in a leukemia stem cell still capable of self-renewal, the same mutation would be expected to persist at relapse (and probably be present at a higher ratio). Further changes, such as amplification of the mutant gene or loss of the wild-type allele (such as through loss of heterozygosity or gene conversion), might occur later, altering the mutant-to-wild-type ratio (and possibly bringing about further growth advantage). In cases where the mutation occurs later, the subpopulation of cells harboring the mutation might expand, but since the mutation was not in the stem cell population, it might be lost at relapse. Intrinsic to this model is the concept that leukemia cells with and without the mutation are present, accounting for the mixed patterns seen on the FLT3/ITD assays.
Conclusions and future directions
To summarize, FLT3 activating mutations occur in 30% of AML cases and are therefore the most common molecular abnormality in that disease. The mutations are especially common in M3 and patients with normal cytogenetics, but relatively rare in core-binding factor leukemias and those cases with poor-risk cytogenetics. In children below the age of 10 years, the mutations are uncommon. Non-M3 AML patients with FLT3/ ITD mutations typically have high WBC counts and packed bone marrows, and, if treated with older '7 þ 3'-type regimens, clearly have a worse prognosis than patients lacking the mutation. It is possible that a more intense treatment regimen may counter this effect on outcome, but longer follow-up is needed to determine this. The clinical impact of D835 mutations is still unclear, due to their relative rarity and the short period of follow-up currently available.
FLT3 can now be confidently added to the growing list of tyrosine kinases associated with malignancy. AML cases harboring FLT3 activating mutations clearly represent a large and important newly recognized subset of this disease, and, as a result, screening for the presence of these mutations at diagnosis and relapse will likely become incorporated into standard of care practice in AML. 157 Many questions about the role of FLT3 in leukemia remain, however, particularly relating to its importance in leukemogenesis and to how successful FLT3-directed therapies will ultimately prove to be. A model explaining the loss of some FLT3/ITD mutations at relapse.
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